A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of ...

How AI, robotics, and precision medicine are transforming cancer care—bridging hope, technology, and humanity in the ongoing ...

Bionova Scientific announced Thursday it would bring 200 new jobs to The Woodlands over the next several years, bolstering ...

We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...

While some practices remain controversial or speculative, biohackers are united by a shared curiosity: how can we engineer ...

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a ...

For kids with the condition, day-to-day activities like going to school or playing with friends can lead to life-threatening ...

The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

The grantmaking organization Open Philanthropy has awarded funding for a University of California San Diego technology ...